Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: a retrospective analysis

Abstract Background Fatty acid metabolism is reportedly associated with various cancers. However, the role of pretreatment serum free fatty acid (FFA) levels in diffuse large B-cell lymphoma (DLBCL) prognosis is still unclear, and our study aimed to better elucidate its influence on clinical outcome...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Liping Fan, Qiuyan Lin, Xiaoling Huang, Danhui Fu, Haobo Huang
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	DLBCL Free fatty acid Prognostic factor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c7a1367be8e048e487a90f69ce876e94
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c7a1367be8e048e487a90f69ce876e94
record_format	dspace
spelling	oai:doaj.org-article:c7a1367be8e048e487a90f69ce876e942021-11-28T12:27:41ZPrognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: a retrospective analysis10.1186/s12885-021-08963-61471-2407https://doaj.org/article/c7a1367be8e048e487a90f69ce876e942021-11-01T00:00:00Zhttps://doi.org/10.1186/s12885-021-08963-6https://doaj.org/toc/1471-2407Abstract Background Fatty acid metabolism is reportedly associated with various cancers. However, the role of pretreatment serum free fatty acid (FFA) levels in diffuse large B-cell lymphoma (DLBCL) prognosis is still unclear, and our study aimed to better elucidate its influence on clinical outcomes. Methods The medical records of 221 newly diagnosed DLBCL patients admitted to Fujian Medical University Union Hospital from January 2011 to December 2016 were analysed retrospectively. Receiver operating characteristic curve analysis was used to determine a cut-off value for pretreatment serum FFA levels for prognostic prediction in DLBCL patients. The relationship between pretreatment serum FFA levels and clinical and laboratory parameters was analysed. Univariate and multivariate analyses were used to assess prognostic factors for overall survival (OS) and progression-free survival (PFS). Results Newly diagnosed DLBCL patients with high pretreatment serum FFA levels (≥0.495 mmol/l) had more B symptoms, higher serum lactate dehydrogenase levels (> upper limit of normal), >1 extranodal site, and higher International Prognostic Index score (3–5) compared to those with low pretreatment serum FFA levels (<0.495 mmol/l). Higher serum FFA levels were independent prognostic factors for poor OS, but not PFS. Conclusions High pretreatment serum FFA levels are associated with lower survival in untreated DLBCL patients.Liping FanQiuyan LinXiaoling HuangDanhui FuHaobo HuangBMCarticleDLBCLFree fatty acidPrognostic factorNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	DLBCL Free fatty acid Prognostic factor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	DLBCL Free fatty acid Prognostic factor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Liping Fan Qiuyan Lin Xiaoling Huang Danhui Fu Haobo Huang Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: a retrospective analysis
description	Abstract Background Fatty acid metabolism is reportedly associated with various cancers. However, the role of pretreatment serum free fatty acid (FFA) levels in diffuse large B-cell lymphoma (DLBCL) prognosis is still unclear, and our study aimed to better elucidate its influence on clinical outcomes. Methods The medical records of 221 newly diagnosed DLBCL patients admitted to Fujian Medical University Union Hospital from January 2011 to December 2016 were analysed retrospectively. Receiver operating characteristic curve analysis was used to determine a cut-off value for pretreatment serum FFA levels for prognostic prediction in DLBCL patients. The relationship between pretreatment serum FFA levels and clinical and laboratory parameters was analysed. Univariate and multivariate analyses were used to assess prognostic factors for overall survival (OS) and progression-free survival (PFS). Results Newly diagnosed DLBCL patients with high pretreatment serum FFA levels (≥0.495 mmol/l) had more B symptoms, higher serum lactate dehydrogenase levels (> upper limit of normal), >1 extranodal site, and higher International Prognostic Index score (3–5) compared to those with low pretreatment serum FFA levels (<0.495 mmol/l). Higher serum FFA levels were independent prognostic factors for poor OS, but not PFS. Conclusions High pretreatment serum FFA levels are associated with lower survival in untreated DLBCL patients.
format	article
author	Liping Fan Qiuyan Lin Xiaoling Huang Danhui Fu Haobo Huang
author_facet	Liping Fan Qiuyan Lin Xiaoling Huang Danhui Fu Haobo Huang
author_sort	Liping Fan
title	Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: a retrospective analysis
title_short	Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: a retrospective analysis
title_full	Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: a retrospective analysis
title_fullStr	Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: a retrospective analysis
title_full_unstemmed	Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: a retrospective analysis
title_sort	prognostic significance of pretreatment serum free fatty acid in patients with diffuse large b-cell lymphoma in the rituximab era: a retrospective analysis
publisher	BMC
publishDate	2021
url	https://doaj.org/article/c7a1367be8e048e487a90f69ce876e94
work_keys_str_mv	AT lipingfan prognosticsignificanceofpretreatmentserumfreefattyacidinpatientswithdiffuselargebcelllymphomaintherituximaberaaretrospectiveanalysis AT qiuyanlin prognosticsignificanceofpretreatmentserumfreefattyacidinpatientswithdiffuselargebcelllymphomaintherituximaberaaretrospectiveanalysis AT xiaolinghuang prognosticsignificanceofpretreatmentserumfreefattyacidinpatientswithdiffuselargebcelllymphomaintherituximaberaaretrospectiveanalysis AT danhuifu prognosticsignificanceofpretreatmentserumfreefattyacidinpatientswithdiffuselargebcelllymphomaintherituximaberaaretrospectiveanalysis AT haobohuang prognosticsignificanceofpretreatmentserumfreefattyacidinpatientswithdiffuselargebcelllymphomaintherituximaberaaretrospectiveanalysis
_version_	1718407981767327744

Prognostic significance of pretreatment serum free fatty acid in patients with diffuse large B-cell lymphoma in the rituximab era: a retrospective analysis

Ejemplares similares